PixelShine vs. Iterative Reconstruction (IR) Processing of CT Images
Launched by ALGOMEDICA, INC. · Jan 24, 2017
Trial Information
Current as of May 01, 2025
Unknown status
Keywords
ClinConnect Summary
Patients receiving CT scans as part of their standard treatment will be asked to consent to an additional 5 minutes of imaging using very low-dose radiation prior to the conventional-dose CT scan. The prospective review will be performed in two cohorts: Chest CT scans and abdominal CT scans.
Anonymized images will be processed by conventional CT software and compared to the same images processed with machine-learning-based PixelShine. A board-certified radiologist will assess the noise and visual quality of the imaging data.
Study patients will receive approximately 10% more dose than a s...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients must be 18 years of age or older
- • Patients must be able and willing to consent to participate in this project
- • Patients will be scheduled for a standard of care CT scan
- Exclusion Criteria:
- • This study does not investigate either a specific disease or a specific patient population-it only examines and compares images obtained at low radiation exposure post-processed with Algomedica's PixelShine software with conventionally processed images
- • All other patients will be excluded
About Algomedica, Inc.
Algomedica, Inc. is a pioneering clinical trial sponsor dedicated to advancing medical research through innovative therapeutic solutions. With a focus on enhancing patient outcomes, the company specializes in the development and management of clinical trials across various therapeutic areas, including neurology, oncology, and rare diseases. Algomedica leverages cutting-edge technology and a robust network of clinical sites to ensure efficient study design, execution, and data analysis, all while prioritizing patient safety and regulatory compliance. Committed to fostering collaboration among stakeholders, Algomedica is poised to contribute significantly to the future of healthcare through its rigorous research initiatives and commitment to scientific excellence.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials